Women using combined oral contraceptives could be tripling their risk of cryptogenic ischaemic stroke, a study has found.

Researchers found that the first two years of using birth control pills were associated with a 70 percent higher risk of depression than in women who had never used oral contraceptives.

Even after adjusting for other recognized risk factors like smoking, migraines with aura, obesity and hypertension, a study ...

When they first met, Marker showed them a sample of his work: 80 grams of pure progesterone,representing almost one third of the world’s supply ... they agreed to collaborate to develop an oral ...

But there was no link among asthma attacks and older progesterone-only contraceptive pill users. Women taking fewer asthma treatments, such as inhaled or oral steroids, who were taking the ...

"Our late-breaker poster highlights ABI-6250’s preclinical profile and potential as a once-daily oral therapy for chronic ... into the potential for next-generation capsid assembly modulators ...

However, no such increased risk was observed in women using the combined oral contraceptive pill, which contains both oestrogen and progesterone. The study, published in ERJ Open Research ...

Among hormonal methods are low-dose oral contraceptive pills, levonorgestrel implant (Norplant), and medroxyprogesterone (Depo-Provera). Nonhormonal options include the IUD, barrier methods ...

"Our late-breaker poster highlights ABI-6250's preclinical profile and potential as a once-daily oral therapy for chronic HDV infection ... provide further insights into the potential for ...

SOUTH SAN FRANCISCO, CA, USA I April 30, 2025 I Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial evaluating its second-generation oral norovirus .

April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine ... to ...

April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine ...